Please assess the completion status of the following clinical trial:

Trial Title: Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CKD stage 4 patients~* Older than 18 years of age~* Non-diabetic~* Serum phosphorus \> 5.5 mg/dl~Exclusion Criteria:~* Diabetes mellitus~* History of coronary artery disease~* Smokers~* Taking statins or renin-angiotensin blockers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sevelamer (Type: OTHER): None
- calcium acetate (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).